ABTAbbott Laboratories

1. Aug 20, 2026As previously reported in Abbott’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, Abbott is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis (“NEC”) as a result …Regulation FD disclosure · Form 8-K
2. Jul 16, 2026Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance.Earnings release · press release
3. Apr 27, 2026On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.Director or officer change · Form 8-K
4. Apr 17, 2026As previously disclosed in Abbott’s Annual Reports on Form 10-K for the fiscal years ended December 31, 2024 and December 31, 2025, six shareholder derivative lawsuits have been pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation, before the United States …Other event · Form 8-K
5. Apr 16, 2026Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences.Earnings release · press release
6. Mar 23, 2026On March 23, 2026, Abbott Laboratories, an Illinois corporation (“Abbott”), completed the acquisition of Exact Sciences Corporation, a Delaware corporation (“Exact Sciences”), pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among Abbott, Exact Sciences and …Other event · Form 8-K
7. Mar 9, 2026On March 9, 2026, Abbott Laboratories (“Abbott”) completed the public offering and issuance of $20,000,000,000 aggregate principal amount of senior notes, consisting of $1,000,000,000 aggregate principal amount of its Floating Rate Notes due 2029 (the “Floating Rate Notes”), $2,250,000,000 aggregate principal amount …Material agreement entered · Form 8-K
8. Feb 26, 2026On February 23, 2026, Abbott Laboratories (“Abbott”) entered into a pricing agreement (the “Pricing Agreement”), dated February 23, 2026, by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several …Material agreement entered · Form 8-K
9. Feb 20, 2026On February 20, 2026, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s By-Laws to provide that Abbott’s Board of Directors shall consist of twelve persons, effective April 24, 2026.Charter/bylaw amendment or fiscal-year change · Form 8-K
10. Jan 22, 2026Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook.Earnings release · press release
11. Dec 12, 2025On December 12, 2025, Nita Ahuja, M.D. was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.Director or officer change · Form 8-K
12. Nov 21, 2025Notice of Blackout Period to.Employee-plan trading blackout · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.